AlphaTON Capital Corp (Nasdaq: ATON) and its wholly owned oncology-focused subsidiary Tarus Therapeutics, LLC, operating as Cyncado Therapeutics (Cyncado), today issued a recap of data presented on ...
Clinical Trials Arena on MSN
Zymeworks reports Phase I data for ZW191 ADC
"Zymeworks reports Phase I data for ZW191 ADC" was originally created and published by Clinical Trials Arena, a GlobalData ...
Get the latest on Novo Nordisk's Alzheimer's trial, stock outlook, and market risks. See what investors need to know before ...
Preliminary efficacy data, combined with a tolerable safety profile, reinforce the potential of ZW191 in patients with advanced solid tumors, ...
Terns Pharmaceuticals halts its TERN-601 obesity program due to insufficient efficacy and safety concerns. Click here to read ...
TipRanks on MSN
Genmab announces new data from Phase 1/2 RAINFOL-01 trial
Genmab (GMAB) announced updated data from cohort B2 of the Phase 1/2 RAINFOL-01 trial evaluating rinatabart sesutecan, an investigational folate ...
The growing use of GLP-1 receptor agonists may affect the interpretation of oncological FDG PET-CT scans, new research presented today at the 38th Annual Congress of the European Association of ...
Multiple ingredients from prebiotic fibers to bacteria are claimed to trigger the production of appetite-regulating hormones such as GLP-1. But they don’t have the same effects as drugs that linger in ...
SAN DIEGO -- Type 2 diabetes patients may have a lower risk of venous thromboembolism (VTE) when treated with a GLP-1 receptor agonist, regardless of their obesity status, a database study involving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback